Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 COMPETITIVE INTELLIGENCE
4.4 NORTH AMERICA AND REGIONAL PREVALENCE:
4.5 INDUSTRY INSIGHTS
4.6 KEY MARKETING STRATEGIES FOR THE NORTH AMERICA INSULIN MARKET TYPE 1 & TYPE 2 DIABETES
4.7 MARKETED DRUG ANALYSIS
5 PIPELINE ANALYSIS
6 REGULATORY FRAMEWORK
6.1 REGULATORY FRAMEWORK FOR THE ASIA-PACIFIC INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.1.1 REGULATORY APPROVAL PROCESS
6.1.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.1.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.1.4 LICENSING AND REGISTRATION
6.1.5 POST-MARKETING SURVEILLANCE
6.1.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.2 REGULATORY FRAMEWORK FOR THE NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.2.1 REGULATORY APPROVAL PROCESS
6.2.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.2.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.2.4 LICENSING AND REGISTRATION
6.2.5 POST-MARKETING SURVEILLANCE
6.2.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.3 REGULATORY FRAMEWORK FOR THE SOUTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.3.1 REGULATORY APPROVAL PROCESS
6.3.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.3.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.3.4 LICENSING AND REGISTRATION
6.3.5 POST-MARKETING SURVEILLANCE
6.3.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.4 REGULATORY FRAMEWORK FOR THE EUROPE INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.4.1 REGULATORY APPROVAL PROCESS
6.4.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.4.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.4.4 LICENSING AND REGISTRATION
6.4.5 POST-MARKETING SURVEILLANCE
6.4.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6.5 REGULATORY FRAMEWORK FOR THE MIDDLE EAST & AFRICA (MEA) INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
6.5.1 REGULATORY APPROVAL PROCESS
6.5.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.5.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE)
6.5.4 LICENSING AND REGISTRATION
6.5.5 POST-MARKETING SURVEILLANCE
6.5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF DIABETES
7.1.2 GROWING ADOPTION OF INSULIN THERAPIES FOR TYPE 1 AND TYPE 2 DIABETES
7.1.3 INTEGRATION OF AUTOMATED INSULIN DELIVERY (AID)
7.1.4 INCREASING TECHNOLOGICAL INNOVATIONS FOR INSULIN
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS OF HIGH DOSAGE OF INSULIN
7.2.2 HIGH PRODUCTION AND DEVELOPMENT COSTS ASSOCIATED WITH INSULIN
7.3 OPPORTUNITIES
7.3.1 ADVANCEMENTS IN INSULIN FORMULATION AND DELIVERY TECHNOLOGIES
7.3.2 REVOLUTIONIZING DIABETES MANAGEMENT WITH NEEDLE-FREE INSULIN
7.3.3 INCREASING PHARMACEUTICAL INVESTMENTS AND STRATEGIC COLLABORATIONS
7.4 CHALLENGES
7.4.1 INSULIN ACCESSIBILITY CHALLENGES IN RURAL AND UNDERSERVED REGIONS
7.4.2 LIMITED SHELF LIFE ASSOCIATED WITH ORAL INSULIN
8 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE
8.1 OVERVIEW
8.2 TYPE 2 DIABETES
8.3 TYPE 1 DIABETES
9 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE
9.1 OVERVIEW
9.2 ANALOG INSULIN
9.3 HUMAN INSULIN
9.4 OTHERS
10 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 LONG ACTING INSULIN
10.3 RAPID-ACTING INSULIN
10.4 SHORT ACTING INSULIN
10.5 OTHERS
11 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 INSULIN PENS
12.3 VIAL & SYRINGE
12.4 INSULIN PUMPS
12.5 INHALABLE INSULIN
12.6 IMPLANTABLE INSULIN DELIVERY SYSTEMS
13 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT PATIENTS
13.3 GERIATRIC PATIENTS
13.4 PEDIATRIC PATIENTS
14 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE
14.1 OVERVIEW
14.2 BASAL
14.3 BOLUS
14.4 OTHERS
15 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES
15.5 DIABETES CLINICS & SPECIALTY PHARMACIES
16 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILES
19.1 NOVO NORDISK A/S
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 SWOT ANALYSIS
19.1.5 PIPELINE PORTFOLIO
19.1.6 RECENT DEVELOPMENT/ NEWS
19.2 LILLY
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 SWOT ANALYSIS
19.2.5 PRODUCT PORTFOLIO
19.2.6 RECENT DEVELOPMENT
19.3 SANOFI
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENT
19.4 BIOCON
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 SWOT ANALYSIS
19.4.5 PIPELINE PRODUCT PORTFOLIO
19.4.6 RECENT DEVELOPMENT
19.5 LUPIN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 SWOT ANALYSIS
19.5.5 PRODUCT PORTFOLIO
19.5.6 RECENT DEVELOPMENT
19.6 ADOCIA
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 SWOT ANALYSIS
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPMENT
19.7 DIASOME PHARMACEUTICALS, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 SWOT ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 MJ BIOPHARM PVT LTD.
19.8.1 COMPANY SNAPSHOT
19.8.2 SWOT ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 NEKTAR
19.9.1 COMPANY SNAPSHOT
19.9.2 SWOT ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT NEWS
19.1 ORAMED
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 SWOT ANALYSIS
19.10.4 PIPELINE PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPMENT
19.11 SCIGEN PTE. LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 SWOT ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 SHANGHAI FOSUN PHARMACEUTICAL（GROUP）CO., LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENT
19.13 WOCKHARDT
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
20 QUESTIONNAIRE
List of Table
TABLE 1 THE TOP 10 COUNTRIES BY THE NUMBER OF ADULTS WITH DIABETES IN 2021
TABLE 2 DISTRIBUTION OF EXPENDITURE ACROSS REGIONS:
TABLE 3 NUMBER OF ADULTS WITH DIABETES IS EXPECTED TO INCREASE SIGNIFICANTLY IN SEVERAL COUNTRIES:
TABLE 4 REGIONAL DIABETES STATISTICS: PREVALENCE, TREATMENT, AND OUTCOMES
TABLE 5 NORTH AMERICA CLINICAL TRIAL MARKET FOR ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 7 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE NORTH AMERICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES
TABLE 8 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 NORTH AMERICA TYPE 2 DIABETES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 NORTH AMERICA TYPE 1 DIABETES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 12 NORTH AMERICA ANALOG INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 NORTH AMERICA HUMAN INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 NORTH AMERICA LONG ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA RAPID-ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 NORTH AMERICA SHORT ACTING INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 NORTH AMERICA OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 21 NORTH AMERICA MALE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA FEMALE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA INSULIN PENS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA VIAL & SYRINGE IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA INSULIN PUMPS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA INHALABLE INSULIN IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA IMPLANTABLE INSULIN DELIVERY SYSTEMS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA ADULT PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA GERIATRIC PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA PEDIATRIC PATIENTS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA BASAL IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA BOLUS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA OTHERS IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA RETAIL PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA HOSPITAL PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA ONLINE PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA DIABETES CLINICS & SPECIALTY PHARMACIES IN INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 51 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 54 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 55 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 56 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 57 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 58 U.S. INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 59 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 62 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 63 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 64 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 65 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 66 CANADA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 67 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY ABSORPTION SITE, 2018-2032 (USD THOUSAND)
TABLE 70 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 71 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY SOURCE, 2018-2032 (USD THOUSAND)
TABLE 72 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DELIVERY METHOD, 2018-2032 (USD THOUSAND)
TABLE 73 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 74 MEXICO INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SEGMENTATION
FIGURE 2 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DROC ANALYSIS
FIGURE 4 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SEGMENTATION
FIGURE 10 TWO SEGMENTS COMPRISE THE NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY TYPE
FIGURE 11 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING PREVALENCE OF DIABETES IS EXPECTED TO DRIVE THE NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 TYPE 2 DIABETES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 15 TOP 10 COUNTRIES BY THE NUMBER OF ADULTS WITH DIABETES IN 2021
FIGURE 16 NORTH AMERICA HEALTHCARE EXPENDITURE FOR DIABETES
FIGURE 17 NUMBER OF PEOPLE WITH DIABETES IN 2045 (MILLIONS)
FIGURE 18 DROC ANALYSIS
FIGURE 19 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, 2024
FIGURE 20 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 21 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, CAGR (2025-2032)
FIGURE 22 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, 2024
FIGURE 24 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, 2025 TO 2032 (USD THOUSAND)
FIGURE 25 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, CAGR (2025-2032)
FIGURE 26 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY SOURCE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, 2024
FIGURE 28 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 29 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, CAGR (2025-2032)
FIGURE 30 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 31 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, 2024
FIGURE 32 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 33 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, CAGR (2025-2032)
FIGURE 34 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY GENDER, LIFELINE CURVE
FIGURE 35 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, 2024
FIGURE 36 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, 2025 TO 2032 (USD THOUSAND)
FIGURE 37 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, CAGR (2025-2032)
FIGURE 38 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 39 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, 2024
FIGURE 40 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, 2025 TO 2032 (USD THOUSAND)
FIGURE 41 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, CAGR (2025-2032)
FIGURE 42 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, 2024
FIGURE 44 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, 2025 TO 2032 (USD THOUSAND)
FIGURE 45 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, CAGR (2025-2032)
FIGURE 46 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY ABSORPTION SITE, LIFELINE CURVE
FIGURE 47 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, 2024
FIGURE 48 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 49 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 50 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: SNAPSHOT (2024)
FIGURE 52 NORTH AMERICA INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES: COMPANY SHARE 2024 (%)
